

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

DPYSL4 RABBIT PAB

Cat.#: S213449

Product Name: Anti-DPYSL4 Rabbit Polyclonal Antibody Synonyms: CRMP3, DRP-4, ULIP4 UNIPROT ID: 014531 (Gene Accession - NP_006417) Background: Collapsin response mediator protein 3 is an enzyme that in humans is encoded by the CRMP3 gene.It is necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. And plays a role in axon guidance, neuronal growth cone collapse and cell migration.Homotetramer, and heterotetramer with CRMP1, DPYSL2, DPYSL3 or DPYSL5. Interacts with PLEXA1. Phosphorylated upon DNA damage, probably by ATM or ATR. Immunogen: Synthetic peptide of human DPYSL4 Applications: ELISA, WB, IHC Recommended Dilutions: IHC: 25-100;WB: 500-1000;ELISA: 1000-5000 Host Species: Rabbit Clonality: Rabbit Polyclonal Isotype: Immunogen-specific rabbit IgG Purification: Antigen affinity purification Species Reactivity: Human, Mouse, Rat Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol **Research Areas:** Neuroscience Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Product Description

Pioneering GTPase and Oncogene Product Development since 2010



Immunohistochemistry analysis of paraffin embedded Human cervical cancer tissue using 213449(DPYSL4 Antibody) at a dilution of 1/15(Cytoplasm).



The image on the left is immunohistochemistry of In comparision with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue paraffin-embedded Human ovarian cancer tissue using 213449(Anti-DPYSL4 Antibody) at a dilution of 1/15.



In comparision with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with the synthetic peptide and then with 213449(Anti-DPYSL4 Antibody) at dilution 1/15.



is first treated with synthetic peptide and then with D160205(Anti-DPYSL4 Antibody) at dilution 1/15.



250-



Product Description

Pioneering GTPase and Oncogene Product Development since 2010